| Literature DB >> 34560555 |
Gloria M Gager1, Dirk von Lewinski2, Harald Sourij3, Bernd Jilma4, Ceren Eyileten5, Krzysztof Filipiak6, Martin Hülsmann7, Jacek Kubica8, Marek Postula5, Jolanta M Siller-Matula9.
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors present a class of antidiabetic drugs, which inhibit renal glucose reabsorption resulting in the elevation of urinary glucose levels. Within the past years, SGLT2 inhibitors have become increasingly relevant due to their effects beyond glycemic control in patients with type 2 diabetes (T2DM). Although dedicated large trials demonstrated cardioprotective effects of SGLT2 inhibitors, the exact mechanisms responsible for those benefits have not been fully identified. Alterations in Ca2+ signaling and oxidative stress accompanied by excessive reactive oxygen species (ROS) production, fibrosis and inflammatory processes form cornerstones of potential molecular targets for SGLT2 inhibitors. This review focused on three hypotheses for SGLT2 inhibitor-mediated cardioprotection: ion homeostasis, oxidative stress and endothelial dysfunction.Entities:
Keywords: Endothelial dysfunction; Fibrosis; Heart failure; Inflammation; Ion homeostasis; Oxidative stress; SGLT2 inhibitors
Mesh:
Substances:
Year: 2021 PMID: 34560555 DOI: 10.1016/j.biopha.2021.112169
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529